Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER × Osteosarcoma × fluzoparib × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Ovarian Neoplasms 9 Breast Neoplasms 5 Sarcoma 3 Triple Negative Breast Neoplasms 2 Prostatic Neoplasms 2 Neoplasm Metastasis 2 Fallopian Tube Neoplasms 2 Carcinoma, Non-Small-Cell Lung 2 Small Cell Lung Carcinoma 1 Sarcoma, Ewing 1 SCLC, Extensive Stage 1 Recurrence 1 Platinum-sensitive Relapsed Ovarian Cancer 1 Osteosarcoma 1 Neoplasms 1 Nasopharyngeal Neoplasms 1 Nasopharyngeal Carcinoma 1 Kenny-Caffey syndrome, Type 1 1 Her-2 Negative Breast Cancer 1 Fludzoparib" and Anti-angiogenic 1 Female Breast Cancer Patients 1 Esophageal Squamous Cell Carcinoma 1 Endometrial Neoplasms 1 Colorectal Neoplasms 1 Breast Cancer Metastatic 1 Advanced HER2 Negative Breast Carcinoma HRD+Breast Cancer 1

Interventions

Ifosfamide 20 Methotrexate 19 Cyclophosphamide 18 Doxorubicin 16 Cisplatin 13 Gemcitabine 10 Filgrastim 10 Etoposide 10 Leucovorin 8 fludarabine 7 apatinib 7 Radiotherapy 6 Nivolumab 6 Neoadjuvant Therapy 6 Drug Therapy 6 Zoledronic Acid 5 Vincristine 5 Temozolomide 5 Mesna 5 Irinotecan 5 Granulocyte Colony-Stimulating Factor 5 Docetaxel 5 Carboplatin 5 regorafenib 4 pegfilgrastim 4 glucarpidase 4 cabozantinib 4 Topotecan 4 Surveys and Questionnaires 4 Sunitinib 4

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06074692 2023-10-31

PRIMA

Ruijin Hospital

Phase 2 Recruiting

Sarcoma, Osteosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡